EyePoint Pharmaceuticals
NEWS
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
EyePoint Pharmaceuticals’ treatment for wet age-related macular degeneration showed comparable results to Regeneron’s Eylea with a less frequent dosing regimen.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It was yet another busy week for clinical trial announcements. Take a look.
It was a busy week for clinical trial news. Read on for more information.
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second Phase III trial of Yutiq (fluocinolone acetonide intravitreal implant) for treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
JOBS
IN THE PRESS